Oral anticoagulation in paediatric patients: dose requirements and complications.

Tait, RC; Ladusans, E J; El-Metaal, M; Patel, Rakhee; Will, Andrew

doi:10.1136/adc.74.3.228

Cited by 35 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The epidemiology of venous TE within the tertiary paediatric setting has been reported in the international literature with increasing frequency. 1,3,4,[7][8][9][10][11][12][13][14][15][16][17] Whether these international descriptions reflect local experience has not previously been investigated. The use of differing medical and surgical approaches to conditions such as cancer, congenital heart disease and gastrointestinal disorders may well yield variable thrombotic complication rates.…”

Section: Discussionmentioning

confidence: 99%

Venous thromboembolic disease: A single‐centre case series study

Newall

Wallace

Crock

et al. 2006

J Paediatrics Child Health

View full text Add to dashboard Cite

In this single-centre registry, venous thrombosis in infants and children occurred with greater frequency than has previously been reported and its epidemiology varied. Central venous catheterisation continues to be a common precipitant to venous thrombosis. Optimal diagnostic and treatment interventions for venous thromboembolism have not yet been determined for infants and children, despite the significant incidence of long-term sequelae.

show abstract

Section: Discussionmentioning

confidence: 99%

Venous thromboembolic disease: A single‐centre case series study

Newall

Wallace

Crock

et al. 2006

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…In children after cardiac surgery for prosthetic valve replacement or the Fontan operation, oral anticoagulation therapy is used for primary prophylaxis against thromboembolism. [1] The paediatric experience is, however, somewhat limited and guidelines are usually derived from the adult recommendations. [2] In general, a target international normalised ratio (INR) of 2.0–3.0 is aimed for post‐Fontan surgery or secondary prophylaxis after thromboembolic complications, and INR of 3.0–4.0 for mechanical valve replacement.…”

mentioning

confidence: 99%

“…[2] In general, a target international normalised ratio (INR) of 2.0–3.0 is aimed for post‐Fontan surgery or secondary prophylaxis after thromboembolic complications, and INR of 3.0–4.0 for mechanical valve replacement. [1,2]…”

mentioning

confidence: 99%

Low dose oral anticoagulation therapy in Chinese children with congenital heart disease

Cheung

1998

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…Because LMWH,14‐16 warfarin,17, 18 and aspirin19 have already been reported to be effective for the prevention of recurrent venous thromboembolism, these reports support anticoagulant therapy by our alternative regimen to prevent PVS following IVR. In addition, the safety of anticoagulant therapy has been reported for pediatric populations 20‐24. We concluded that stronger anticoagulation is necessary for preventing recurrent PVS, although this 3‐agent anticoagulant therapy combining LMWH, warfarin, and aspirin may cause an excessive anticoagulant state.…”

Section: Discussionmentioning

confidence: 88%

Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation

Sanada¹,

Kawano²,

Mizuta³

et al. 2010

Liver Transpl

View full text Add to dashboard Cite

Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver failure. Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem. Anticoagulant therapy for PVS is an important factor for preventing short-term recurrence following IVR, but no established regimen has been reported for the prevention of recurrent PVS following IVR. In our population of 197 pediatric patients who underwent living donor liver transplantation (LDLT), 22 patients (22/197, 11.2%) suffered PVS. In the 9 earliest patients, unfractionated heparin was the only anticoagulant therapy given following IVR. In the 13 more recent patients, 3-agent anticoagulant therapy using low-molecular-weight heparin, warfarin, and aspirin was employed. In the initial group of 9 patients, 5 patients (55.6%) suffered recurrent PVS and required repeat balloon dilatation. Among the 13 more recent patients, none experienced recurrent PVS (P ¼ 0.002). In conclusion, our 3-agent anticoagulant therapy following IVR for PVS in pediatric LDLT can be an effective therapeutic strategy for preventing recurrent PVS. Liver Transpl 16:332-339,

show abstract

Oral anticoagulation in paediatric patients: dose requirements and complications.

Abstract: The lack of oral anticoagulant guidelines specific to paediatric practice has led to the adoption of

Cited by 35 publications

References 11 publications

Venous thromboembolic disease: A single‐centre case series study

Venous thromboembolic disease: A single‐centre case series study

Low dose oral anticoagulation therapy in Chinese children with congenital heart disease

Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation

Contact Info

Product

Resources

About